$INSP
Inspire Medical Systems, Inc. Stock $insp

$insp Overview Financials Valuation SEC Filings Company Website

2019 Q2 Form 10-Q Financial Statement

#000160955019000028 Filed on May 07, 2019

Income Statement

Concept	2019 Q2	2019 Q1	2018 Q1
Revenue	$18.03M	$16.25M	$10.04M
YoY Change	64.86%	61.82%	89.58%
Cost Of Revenue	$3.094M	$2.854M	$2.294M
YoY Change	47.19%	24.41%	91.17%
Gross Profit	$14.94M	$13.40M	$7.748M
YoY Change	69.06%	72.9%	88.93%
Gross Profit Margin	82.84%	82.44%	77.16%
Selling, General & Admin	$20.27M	$19.57M	$11.21M
YoY Change	59.11%	74.58%	69.08%
% of Gross Profit	135.69%	146.09%	144.68%
Research & Development	$2.846M	$2.603M	$1.730M
YoY Change	64.03%	50.46%	8.81%
% of Gross Profit	19.05%	19.43%	22.33%
Depreciation & Amortization	$110.0K	$103.0K	$90.00K
YoY Change	10.0%	14.44%	125.0%
% of Gross Profit	0.74%	0.77%	1.16%
Operating Expenses	$23.11M	$22.17M	$12.94M
YoY Change	59.7%	71.31%	57.46%
Operating Profit	-$8.176M	-$8.777M	-$5.195M
YoY Change	45.04%	68.95%	26.12%
Interest Expense	$523.0K	$537.0K	$1.385M
YoY Change	-4.91%	-61.23%	-484.72%
% of Operating Profit
Other Income/Expense, Net	$526.0K	$511.0K	-$1.306M
YoY Change	-340.18%	-139.13%
Pretax Income	-$7.650M	-$8.266M	-$6.501M
YoY Change	30.64%	27.15%	45.11%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$7.650M	-$8.266M	-$6.501M
YoY Change	30.64%	27.15%	45.08%
Net Earnings / Revenue	-42.42%	-50.87%	-64.74%
Basic Earnings Per Share
Diluted Earnings Per Share	-$322.1K	-$352.8K	-$321.1K
COMMON SHARES
Basic Shares Outstanding	23.81M shares	23.44M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2019 Q2	2019 Q1	2018 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$158.6M	$177.0M	$17.90M
YoY Change	27.9%	888.83%
Cash & Equivalents	$51.27M	$101.9M	$11.15M
Short-Term Investments	$107.4M	$75.10M	$6.800M
Other Short-Term Assets	$5.600M	$1.400M	$2.200M
YoY Change	460.0%	-36.36%
Inventory	$3.561M	$3.106M	$3.400M
Prepaid Expenses	$5.596M	$1.726M
Receivables	$9.465M	$7.036M	$3.500M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$177.2M	$199.3M	$26.90M
YoY Change	33.26%	640.78%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.826M	$974.0K	$900.0K
YoY Change	102.89%	8.22%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$6.100M
YoY Change
Other Assets	$400.0K	$100.0K
YoY Change
Total Long-Term Assets	$8.323M	$824.0K	$1.000M
YoY Change	824.78%	-17.6%
TOTAL ASSETS
Total Short-Term Assets	$177.2M	$199.3M	$26.90M
Total Long-Term Assets	$8.323M	$824.0K	$1.000M
Total Assets	$185.6M	$200.1M	$27.90M
YoY Change	38.58%	617.18%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.700M	$3.200M	$3.900M
YoY Change	22.73%	-17.95%
Accrued Expenses	$5.980M	$7.740M	$3.300M
YoY Change	35.91%	134.55%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due			$700.0K
YoY Change
Total Short-Term Liabilities	$8.661M	$11.17M	$7.900M
YoY Change	-6.87%	41.38%
LONG-TERM LIABILITIES
Long-Term Debt	$24.40M	$24.40M	$23.90M
YoY Change	10.91%	2.09%
Other Long-Term Liabilities			$1.000M
YoY Change
Total Long-Term Liabilities	$24.40M	$24.40M	$24.90M
YoY Change	10.91%	-2.01%
TOTAL LIABILITIES
Total Short-Term Liabilities	$8.661M	$11.17M	$7.900M
Total Long-Term Liabilities	$24.40M	$24.40M	$24.90M
Total Liabilities	$33.08M	$36.10M	$32.80M
YoY Change	5.67%	10.05%
SHAREHOLDERS EQUITY
Retained Earnings	-$162.8M	-$155.2M
YoY Change
Common Stock	$24.00K	$24.00K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$152.5M	$157.4M	-$4.900M
YoY Change
Total Liabilities & Shareholders Equity	$185.6M	$200.1M	$27.90M
YoY Change	38.58%	617.18%

Cashflow Statement

Concept	2019 Q2	2019 Q1	2018 Q1
OPERATING ACTIVITIES
Net Income	-$7.650M	-$8.266M	-$6.501M
YoY Change	30.64%	27.15%	45.08%
Depreciation, Depletion And Amortization	$110.0K	$103.0K	$90.00K
YoY Change	10.0%	14.44%	125.0%
Cash From Operating Activities	-$12.89M	-$10.94M	-$6.418M
YoY Change	110.28%	70.49%	19.74%
INVESTING ACTIVITIES
Capital Expenditures	-$950.0K	$275.0K	$7.000K
YoY Change	1800.0%	3828.57%	-103.33%
Acquisitions
YoY Change
Other Investing Activities	-$38.06M	$16.23M	$430.0K
YoY Change	-918.49%	3674.42%
Cash From Investing Activities	-$39.03M	$15.96M	$425.0K
YoY Change	-950.33%	3654.35%	-302.38%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	1.250M	-$366.0K	$8.185M
YoY Change	-98.89%	-104.47%	-67.81%
NET CHANGE
Cash From Operating Activities	-12.89M	-$10.94M	-$6.418M
Cash From Investing Activities	-39.03M	$15.96M	$425.0K
Cash From Financing Activities	1.250M	-$366.0K	$8.185M
Net Change In Cash	-50.67M	$4.657M	$2.192M
YoY Change	-145.77%	112.45%	-88.96%
FREE CASH FLOW
Cash From Operating Activities	-$12.89M	-$10.94M	-$6.418M
Capital Expenditures	-$950.0K	$275.0K	$7.000K
Free Cash Flow	-$11.94M	-$11.22M	-$6.425M
YoY Change	96.38%	74.58%	24.76%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2019Q1	dei	Entity Registrant Name EntityRegistrantName	Inspire Medical Systems, Inc.
CY2019Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001609550
CY2019Q1	dei	Document Type DocumentType	10-Q
CY2019Q1	dei	Document Period End Date DocumentPeriodEndDate	2019-03-31
CY2019Q1	dei	Amendment Flag AmendmentFlag	false
CY2019Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2019Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2019Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2019Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2019Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2019Q1	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2019Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	23805187	shares
CY2019Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2019
CY2019Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2019Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2018Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2019Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2018Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2019Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	23503010	shares
CY2018Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	23401675	shares
CY2019Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	23503010	shares
CY2018Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	23401675	shares
CY2018Q2	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	0.1504
CY2019Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	16000	USD
CY2018Q4	us-gaap	Fair Value Assets Level1 To Level2 Transfers Amount FairValueAssetsLevel1ToLevel2TransfersAmount	0	USD
CY2019Q1	us-gaap	Fair Value Assets Level2 To Level1 Transfers Amount FairValueAssetsLevel2ToLevel1TransfersAmount	0	USD
CY2018Q4	us-gaap	Fair Value Assets Level2 To Level1 Transfers Amount FairValueAssetsLevel2ToLevel1TransfersAmount	0	USD
CY2019Q1	us-gaap	Fair Value Liabilities Level1 To Level2 Transfers Amount FairValueLiabilitiesLevel1ToLevel2TransfersAmount	0	USD
CY2018Q4	us-gaap	Fair Value Liabilities Level1 To Level2 Transfers Amount FairValueLiabilitiesLevel1ToLevel2TransfersAmount	0	USD
CY2019Q1	us-gaap	Fair Value Liabilities Level2 To Level1 Transfers Amount FairValueLiabilitiesLevel2ToLevel1TransfersAmount	0	USD
CY2018Q4	us-gaap	Fair Value Liabilities Level2 To Level1 Transfers Amount FairValueLiabilitiesLevel2ToLevel1TransfersAmount	0	USD
CY2018Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	0	USD
CY2018Q1	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	100000	USD
CY2018Q1	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	100000	USD
CY2019Q1	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	USD
CY2018Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	USD
CY2019Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	101945000	USD
CY2018Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	97288000	USD
CY2019Q1	us-gaap	Short Term Investments ShortTermInvestments	75069000	USD
CY2018Q4	us-gaap	Short Term Investments ShortTermInvestments	90922000	USD
CY2019Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	7036000	USD
CY2018Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	6667000	USD
CY2019Q1	us-gaap	Inventory Net InventoryNet	3106000	USD
CY2018Q4	us-gaap	Inventory Net InventoryNet	2667000	USD
CY2019Q1	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	1387000	USD
CY2018Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	1734000	USD
CY2019Q1	us-gaap	Assets Current AssetsCurrent	188543000	USD
CY2018Q4	us-gaap	Assets Current AssetsCurrent	199278000	USD
CY2019Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	974000	USD
CY2018Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	802000	USD
CY2019Q1	us-gaap	Investments And Other Noncurrent Assets InvestmentsAndOtherNoncurrentAssets	89000	USD
CY2018Q4	us-gaap	Investments And Other Noncurrent Assets InvestmentsAndOtherNoncurrentAssets	0	USD
CY2019Q1	us-gaap	Assets Assets	189606000	USD
CY2018Q4	us-gaap	Assets Assets	200080000	USD
CY2019Q1	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	3203000	USD
CY2018Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	3429000	USD
CY2019Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4623000	USD
CY2018Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	7726000	USD
CY2019Q1	us-gaap	Liabilities Current LiabilitiesCurrent	7826000	USD
CY2018Q4	us-gaap	Liabilities Current LiabilitiesCurrent	11155000	USD
CY2019Q1	us-gaap	Long Term Notes Payable LongTermNotesPayable	24364000	USD
CY2018Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	24926000	USD
CY2019Q1	us-gaap	Liabilities Liabilities	32190000	USD
CY2018Q4	us-gaap	Liabilities Liabilities	36081000	USD
CY2019Q1	us-gaap	Common Stock Value CommonStockValue	24000	USD
CY2018Q4	us-gaap	Common Stock Value CommonStockValue	23000	USD
CY2019Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	312555000	USD
CY2018Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	310941000	USD
CY2019Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	16000	USD
CY2018Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-52000	USD
CY2019Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-155179000	USD
CY2018Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-146913000	USD
CY2019Q1	us-gaap	Stockholders Equity StockholdersEquity	157416000	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	163999000	USD
CY2019Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	189606000	USD
CY2018Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	200080000	USD
CY2019Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	16250000	USD
CY2018Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	10042000	USD
CY2019Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	2854000	USD
CY2018Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	2294000	USD
CY2019Q1	us-gaap	Gross Profit GrossProfit	13396000	USD
CY2018Q1	us-gaap	Gross Profit GrossProfit	7748000	USD
CY2019Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2603000	USD
CY2018Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1730000	USD
CY2019Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	19570000	USD
CY2018Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	11213000	USD
CY2019Q1	us-gaap	Operating Expenses OperatingExpenses	22173000	USD
CY2018Q1	us-gaap	Operating Expenses OperatingExpenses	12943000	USD
CY2019Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-8777000	USD
CY2018Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-5195000	USD
CY2019Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	1086000	USD
CY2018Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	60000	USD
CY2019Q1	us-gaap	Interest Expense InterestExpense	537000	USD
CY2018Q1	us-gaap	Interest Expense InterestExpense	1385000	USD
CY2019Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-38000	USD
CY2018Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	19000	USD
CY2019Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	511000	USD
CY2018Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1306000	USD
CY2019Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-8266000	USD
CY2018Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-6501000	USD
CY2019Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2018Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2019Q1	us-gaap	Profit Loss ProfitLoss	-8266000	USD
CY2018Q1	us-gaap	Profit Loss ProfitLoss	-6501000	USD
CY2019Q1	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	68000	USD
CY2018Q1	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	0	USD
CY2019Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-8198000	USD
CY2018Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-6501000	USD
CY2019Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.35
CY2018Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-5.05
CY2019Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	23441560	shares
CY2018Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	90000	USD
CY2018Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	1286633	shares
CY2018Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	163999000	USD
CY2019Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	166000	USD
CY2019Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	58000	USD
CY2019Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	1391000	USD
CY2019Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	68000	USD
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	-8266000	USD
CY2019Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	157416000	USD
CY2017Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1327000	USD
CY2018Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	186000	USD
CY2018Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	55000	USD
CY2018Q1	us-gaap	Net Income Loss NetIncomeLoss	-6501000	USD
CY2018Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-4933000	USD
CY2019Q1	us-gaap	Profit Loss ProfitLoss	-8266000	USD
CY2018Q1	us-gaap	Profit Loss ProfitLoss	-6501000	USD
CY2019Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	103000	USD
CY2018Q1	us-gaap	Share Based Compensation ShareBasedCompensation	55000	USD
CY2019Q1	us-gaap	Investment Income Amortization Of Discount InvestmentIncomeAmortizationOfDiscount	309000	USD
CY2018Q1	us-gaap	Investment Income Amortization Of Discount InvestmentIncomeAmortizationOfDiscount	0	USD
CY2019Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	110000	USD
CY2018Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	213000	USD
CY2019Q1	us-gaap	Share Based Compensation ShareBasedCompensation	1391000	USD
CY2019Q1	insp	Sharebased Compensation Noncash Services SharebasedCompensationNoncashServices	58000	USD
CY2018Q1	insp	Sharebased Compensation Noncash Services SharebasedCompensationNoncashServices	0	USD
CY2019Q1	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	0	USD
CY2018Q1	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	-718000	USD
CY2019Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	141000	USD
CY2018Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	0	USD
CY2019Q1	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	385000	USD
CY2018Q1	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	-399000	USD
CY2019Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	439000	USD
CY2018Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-276000	USD
CY2019Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-254000	USD
CY2018Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1761000	USD
CY2019Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-222000	USD
CY2018Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	918000	USD
CY2019Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-3096000	USD
CY2018Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-825000	USD
CY2019Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-10942000	USD
CY2018Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-6418000	USD
CY2019Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	275000	USD
CY2018Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	7000	USD
CY2019Q1	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	40573000	USD
CY2018Q1	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	4642000	USD
CY2019Q1	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	56804000	USD
CY2018Q1	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	5074000	USD
CY2019Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	15956000	USD
CY2018Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	425000	USD
CY2019Q1	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	0	USD
CY2018Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	185000	USD
CY2018Q1	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	8000000	USD
CY2019Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	165000	USD
CY2019Q1	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	531000	USD
CY2018Q1	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0	USD
CY2019Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-366000	USD
CY2018Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	8185000	USD
CY2019Q1	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	9000	USD
CY2018Q1	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	0	USD
CY2019Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	4657000	USD
CY2018Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	2192000	USD
CY2018Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	97288000	USD
CY2017Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	8955000	USD
CY2019Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	101945000	USD
CY2018Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	11147000	USD
CY2019Q1	us-gaap	Interest Paid Net InterestPaidNet	771000	USD
CY2018Q1	us-gaap	Interest Paid Net InterestPaidNet	347000	USD
CY2019Q1	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	0	USD
CY2018Q1	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	103000	USD
CY2018Q2	insp	Reclassification Of Warrant Liability To Additional Paid In Capital ReclassificationOfWarrantLiabilityToAdditionalPaidInCapital	900000	USD
CY2019Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;font-weight:700;line-height:120%;">Use of Estimates</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;font-weight:400;line-height:120%;">The </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;line-height:120%;">preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts and disclosures reported in the financial statements. We use significant judgment when making estimates related to the allowance for doubtful accounts, inventory reserves, warranty reserves, and the valuations of our common stock prior to our IPO, share-based awards, and certain of our previously outstanding preferred stock warrants. We base our estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;font-weight:400;line-height:120%;">.</span></div>
CY2018Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-100000	USD
CY2018Q1	us-gaap	Available For Sale Securities Gross Realized Gains AvailableForSaleSecuritiesGrossRealizedGains	0	USD
CY2019Q1	us-gaap	Available For Sale Securities Gross Realized Gains AvailableForSaleSecuritiesGrossRealizedGains	0	USD
CY2019Q1	us-gaap	Fair Value Assets Level1 To Level2 Transfers Amount FairValueAssetsLevel1ToLevel2TransfersAmount	0	USD
CY2019Q1	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;font-weight:700;line-height:120%;">Concentration of Credit Risk</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;font-weight:400;line-height:120%;">Financial instruments, which potentially subject us to concentrations of credit risk, consist </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;line-height:120%;">principally of cash equivalents, short-term investments, and accounts receivable</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;font-weight:400;line-height:120%;">. </span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;line-height:120%;">Our investment policy limits investments to certain types of debt securities issued by the U.S. government and its agencies, corporations with investment-grade credit ratings, or commercial paper and money market funds issued by the highest quality financial and non-financial companies. We place restrictions on maturities and concentration by type and issuer. We are exposed to credit risk in the event of a default by the issuers of these securities to the extent recorded on the balance sheets. However, as of</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;font-weight:400;line-height:120%;"> March 31, 2019 and December 31, 2018, </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;line-height:120%;">we limited our credit risk associated with cash equivalents by placing investments with banks we believe are highly creditworthy</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;font-weight:400;line-height:120%;">.</span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:Arial;font-size:10pt;line-height:120%;">We believe that the credit risk in our accounts receivable is mitigated by our credit evaluation process, relatively short collection terms, and dispersion of our customer base. We generally do not require collateral, and losses on accounts receivable have historically been within management's expectations.</span></div>
CY2019Q1	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	900000	USD
CY2018Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	800000	USD
CY2019Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2019Q1	us-gaap	Advertising Expense AdvertisingExpense	3500000	USD
CY2018Q1	us-gaap	Advertising Expense AdvertisingExpense	2200000	USD
CY2019Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2019Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1588000	USD
CY2019Q1	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	933000	USD
CY2018Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	802000	USD
CY2019Q1	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	2173000	USD
CY2018Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	1865000	USD
CY2019Q1	us-gaap	Inventory Net InventoryNet	3106000	USD
CY2018Q4	us-gaap	Inventory Net InventoryNet	2667000	USD
CY2018Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1601000	USD
CY2019Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	614000	USD
CY2018Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	799000	USD
CY2019Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	974000	USD
CY2018Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	802000	USD
CY2018Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	100000	USD
CY2019Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	100000	USD
CY2019Q1	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	3907000	USD
CY2018Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	6490000	USD
CY2019Q1	us-gaap	Interest Payable Current InterestPayableCurrent	0	USD
CY2018Q4	us-gaap	Interest Payable Current InterestPayableCurrent	195000	USD
CY2019Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	716000	USD
CY2018Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1041000	USD
CY2019Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4623000	USD
CY2019Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear	0	USD
CY2018Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	7726000	USD
CY2019Q1	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	75053000	USD
CY2019Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	17000	USD
CY2019Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	1000	USD
CY2019Q1	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	75069000	USD
CY2018Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	90974000	USD
CY2018Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	USD
CY2018Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	52000	USD
CY2018Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	90922000	USD
CY2018Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	0	USD
CY2019Q1	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	0	USD
CY2015Q3	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	100000	USD
CY2019Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	0	USD
CY2019Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	0	USD
CY2019Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	9188000	USD
CY2019Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive	12250000	USD
CY2019Q1	insp	Longterm Debt Maturities Repayments Of Principal Thereafter LongtermDebtMaturitiesRepaymentsOfPrincipalThereafter	3062000	USD
CY2019Q1	us-gaap	Long Term Debt LongTermDebt	24500000	USD
CY2019Q1	us-gaap	Operating Leases Future Minimum Payments Remainder Of Fiscal Year OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear	995000	USD
CY2019Q1	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	952000	USD
CY2019Q1	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	1947000	USD
CY2019Q1	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	300000	USD
CY2018Q1	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	100000	USD
CY2018Q4	insp	Reclassification Of Warrant Liability To Additional Paid In Capital ReclassificationOfWarrantLiabilityToAdditionalPaidInCapital	900000	USD
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2745156	shares
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	12.64
CY2018	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y4M24D
CY2019Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	53750	shares
CY2019Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	53.69
CY2019Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	100089	shares
CY2019Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	1.65
CY2019Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	3304	shares
CY2019Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	32.76
CY2019Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2695513	shares
CY2019Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	13.84
CY2019Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y3M18D
CY2018Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Outstanding SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding	115773000	USD
CY2019Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	1274062	shares
CY2019Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	1.52
CY2019Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P5Y2M12D
CY2019Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Vested SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested	70407000	USD
CY2019Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1391000	USD
CY2018Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	55000	USD
CY2019Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	15600000	USD
CY2019Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y9M18D
CY2019Q1	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	segment
CY2019Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	16250000	USD
CY2018Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	10042000	USD
CY2019Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2702108	shares
CY2018Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	14744767	shares

Files In Submission

Name	View Source	Status
0001609550-19-000028-index-headers.html	Edgar Link	pending
0001609550-19-000028-index.html	Edgar Link	pending
0001609550-19-000028.txt	Edgar Link	pending
0001609550-19-000028-xbrl.zip	Edgar Link	pending
a2019-q1ex31x1.htm	Edgar Link	pending
a2019-q1ex31x2.htm	Edgar Link	pending
a2019-q1ex32x1.htm	Edgar Link	pending
a2019-q1ex32x2.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
insp-20190331.htm	Edgar Link	pending
insp-20190331.xsd	Edgar Link	pending
insp-20190331_cal.xml	Edgar Link	unprocessable
insp-20190331_def.xml	Edgar Link	unprocessable
insp-20190331_g1.jpg	Edgar Link	pending
insp-20190331_htm.xml	Edgar Link	completed
insp-20190331_lab.xml	Edgar Link	unprocessable
insp-20190331_pre.xml	Edgar Link	unprocessable
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$INSP
Inspire Medical Systems, Inc. Stock $insp

2019 Q2 Form 10-Q Financial Statement

#000160955019000028 Filed on May 07, 2019

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$INSP Inspire Medical Systems, Inc. Stock $insp

2019 Q2 Form 10-Q Financial Statement

#000160955019000028 Filed on May 07, 2019

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$INSP
Inspire Medical Systems, Inc. Stock $insp